| 题名 |
抗藥性局部晚期或轉移性乳癌病人的治療選擇－lxabepilone（Ixemptra®） |
| 并列篇名 |
Treatment Options for Drug-Resistant Patients with Locally advanced or Metastatic Breast Cancer: Ixabepilone (Ixempra®) |
| DOI |
10.6880/TJON.202106_21(1).04 |
| 作者 |
徐立凡(Li-Fan Hsu) |
| 关键词 |
Ixabepilone ； Ixempra ； 乳癌 ； 抗藥性 ； 轉移性乳癌 ； breast cancer ； ixabepilone ； ixempra ； resistance ； metastatic breast cancer |
| 期刊名称 |
腫瘤護理雜誌 |
| 卷期/出版年月 |
21卷1期（2021 / 06 / 01） |
| 页次 |
45 - 50 |
| 内容语文 |
繁體中文 |
| 中文摘要 |
乳癌為全球女性好發癌症排名第一。局部晚期或轉移性乳癌病人在用藥選擇上，除了考量病人病況限制外，亦常面臨藥品的抗藥性問題。Ixabepilone屬epothilones類抗腫瘤藥品，機轉為與微管蛋白結合，導致腫瘤細胞無法進行有絲分裂，造成細胞凋亡。但對紫杉醇、蒽環類等具有抗藥性病人，有一定療效。經臨床試驗證實，ixabepilone合併capecitabine相較於單用capecitabine，可延長中位無惡化存活期與客觀緩解率。Ixabepilone已於2021年2月納入健保給付，相信能嘉惠更多乳癌病人。隨著接受本藥治療的病人數增加，值得注意的是，藥品相關監測與注意事項，以及衛教病人面對與處理相關副作用亦是相當重要的課題。 |
| 英文摘要 |
Breast cancer is the most prevalent cancer among women worldwide. Ixabepilone exerts its effect by binding to tubulin, thus preventing mitosis and resulting in apoptosis. Ixabepilone is also effective in patients with resistance to paclitaxel and anthracyclines. The combination of ixabepilone and capecitabine has been clinically shown to extend median progression-free survival and objective remission rates compared to capecitabine alone. Ixabepilone was approved for national health insurance coverage in February 2021, which is expected to benefit more breast cancer patients. It is important to note that as the number of patients treated with this drug increases, monitoring and precautions related to drug administration, as well as patient education, side effects, are also important issues. |
| 主题分类 |
醫藥衛生 >
預防保健與衛生學 醫藥衛生 > 內科 醫藥衛生 > 社會醫學 |
| 参考文献 |
|
